4 completed, 2 unknown, 1 active not recruiting. 3 Phase 3, 2 Phase 2, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Unknown 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
| Phase 4 | 2 | Active not recruiting 1, Completed 1 |
Follow Blushing: new trials by email Literature Review of Blushing trials Research Report on Blushing
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Flush Versus Standard Distance From Saphenofemoral Junction in Endovenous Laser Ablation of Great Saphenous Vein flush endovenous laser ablation of great saphenous vein, standard endovenous laser ablation of great saphenous vein - Varicose Veins Leg | Phase 4 | Completed | Kafrelsheikh University | 200 | 2024-01-21 | 2025-04-06 |
| Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment Masitinib, Placebo, Best Supportive Care - Indolent Systemic Mastocytosis | Phase 3 | Unknown | AB Science | 140 | 2020-07-01 | 2023-05-06 |
| Treatment of Facial Flushing With Botulinum Toxin A Injections botulinum toxin A, Saline Control - Facial Flushing | Phase 4 | Active not recruiting | Northwestern University | 16 | 2014-08-01 | 2026-07-01 |
| Effectiveness of Intracoronary Injection of Eptifibatide in Primary Coronary Intervention in STEMI Patients Eptifibatide - Acute Myocardial Infarction | Phase 2 | Unknown | Assaf-Harofeh Medical Center | 50 | 2009-08-01 | 2009-07-24 |
| Port Will be Flushed Every 3 Months Instead of Every 4-6 Wks, as Recommended by Port Manufacturer. Reduced port-flush schedule - Complication of Catheter | Phase 2 | Completed | University of Louisville | 87 | 2009-03-01 | 2021-07-19 |
| Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Masitinib, Placebo, Best Supportive Care - Indolent Systemic Mastocytosis | Phase 3 | Completed | AB Science | 135 | 2008-12-01 | 2019-12-03 |
| Gabapentin for the Treatment of Hot Flashes in Menopausal Women gabapentin - Hot Flashes, Menopause | Phase 3 | Completed | North Toronto Primary Care Research Network | 200 | 2004-03-01 | 2011-05-23 |
Mastocytosis (2) · Mastocytosis, Systemic (2) · Piebaldism (2) · Pruritus (2) · Hot Flashes (1)
Behavior (7) · Communication (7) · Nonverbal Communication (7) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Albinism (2) · Amino Acid Metabolism, Inborn Errors (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Eye Diseases, Hereditary (2) · Genetic Diseases, Inborn (2) · Hypopigmentation (2) · Immune System Diseases (2) · Mast Cell Activation Disorders (2) · Metabolic Diseases (2) · Metabolism, Inborn Errors (2)
masitinib (2) · Botulinum Toxins, Type A (1) · Eptifibatide (1) · Gabapentin (1)
AB Science (2) · Assaf-Harofeh Medical Center (1) · Kafrelsheikh University (1) · North Toronto Primary Care Research Network (1) · Northwestern University (1) · University of Louisville (1)
United States (3) · France (2) · Canada (1) · Egypt (1) · Germany (1) · Israel (1) · Netherlands (1) · Poland (1) · Romania (1) · Russia (1) · Ukraine (1) · United Kingdom (1)
Cristina Bulai Livideanu, MD, MSc (1) · Debra Butt, MSc MD CCFP (1) · Goetz H Kloecker, MD (1) · Murad Alam, MD (1) · Olivier Lortholary, MD, PhD (1)
PMID 28069279, PMID 28084883, PMID 36048877
2016 (1)